Overview
Welcome to NTT's Investor Center. For your convenience, we provide here a library of company announcements, press releases, a calendar of events, as well as an investor form so that you can request any additional specific information you may require.
NTT
NTT was established in January 2003 to acquire, develop and commercialize novel drug technologies. The first technology acquired by NTT is a drug delivery system named Ethosome. The technology was developed at the Hebrew University and was licensed to the company. Products using the technology are already on the market and are generating revenues. The global transdermal drug delivery market is expected to reach an estimated $21.5 billion by 2010 and $31.5 billion by 20151. The Ethosome technology has a rare combination of characteristics providing a compelling and attractive solution for pharmaceutical and cosmetic companies wishing to enhance their product offerings.
Advisers:
Nominated Adviser
British Linen Advisers
8 Frederick's Place
London EC2R8HY
Tel:+44 (0)20 7710 8800
www.britishlinen.co.uk
Stockbroker
Teather & Greenwood Limited
Beaufort House
15 St. Botolph
London, EC3A 7QR
Tel: +44(0) 207-426 7713
www.teathers.com
Solicitors to the Company (UK and US)
Brown Rudnick Berlack Israels LLP
124 Swan Court Chelsea Street
London SW3 5RU
Tel: +44 (0) 20 7851 6100
www.brownrudnick.com
Solicitors to the Company (Israel)
Meitar Liquornik Geva & Leshem Brandwein,
16 Abba Hillel Silver Road
Ramat Gan 52506
Tel: +972 -3 - 610 31 00
www.meitar.co.il
Accountant
KPMG Somekh Chaikin
17 Ha'arbaa St.
Tel Aviv, Israel
Tel: +972 -3- 684-8000
www.KPMG.com
|
 |
Company Information:
Headquarters: 30 Af Al Pi Chen Street Zichron Yakov 30900, Israel.
CEO: Dan Touitou, B. Pharm, MBA
Investor Relations:
UK
Tim Isaacs
CFO - NTT Inc.
tim@ntt-inc.com
Simon Hudson/Christian Taylor-Wilkinson
Tavistock Communications
shudson@tavistock.co.uk
ctaylor-wilkinson@tavistock.co.uk
Tel: +44 20 7920 3150
Israel
Etty Levin
Novel Therapeutic Technologies Ltd.
etty@ntt-inc.com
Tel: +972-4-639-2995
|
1 - Transdermal Drug Delivery - Technologies Market, and Companies, Jain PharmaBiotech, May 2005
|
|
|
